BioCardia Inc BCDA.OQ BCDA.O is expected to show a fall in quarterly revenue when it reports results on November 13 for the period ending September 30 2024
The Sunnyvale California-based company is expected to report a 44.0% decrease in revenue to $200 thousand from $357 thousand a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for BioCardia Inc is for a loss of $1.19 per share.
The one available analyst rating on the shares is "buy".
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
Wall Street's median 12-month price target for BioCardia Inc is 25.00, above its last closing price of $2.30.
This summary was machine generated November 12 at 03:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments